Primary Prophylaxis of Overt Hepatic Encephalopathy: Is It Time to Consider It?
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J. Hepatol. 2022, 77, 807–824. [Google Scholar] [CrossRef] [PubMed]
- Rose, C.F.; Amodio, P.; Bajaj, J.S.; Dhiman, K.; Montagnese, S.; Taylor-Robinson, S.D.; Vilstrup, H.; Jalan, R. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. J. Hepatol. 2020, 73, 1526–1547. [Google Scholar] [CrossRef] [PubMed]
- Rega, D.; Aiko, M.; Peñaranda, N.; Urios, A.; Gallego, J.J.; Giménez-Garzó, C.; Casanova, F.; Fiorillo, A.; Cabrera-Pastor, A.; San-Miguel, T.; et al. Patients with Minimal Hepatic Encephalopathy Show Altered Thermal Sensitivity and Autonomic Function. J. Clin. Med. 2021, 10, 239. [Google Scholar] [CrossRef] [PubMed]
- Kawaratani, H.; Kondo, Y.; Tatsumi, R.; Kawabe, N.; Tanabe, N.; Sakamaki, A.; Okumoto, K.; Uchida, Y.; Endo, K.; Kawaguchi, T.; et al. Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study. J. Clin. Med. 2022, 11, 1571. [Google Scholar] [CrossRef]
- Sharma, P.; Agrawal, A.; Sharma, B.C.; Sarin, S.K. Prophylaxis of hepatic encephalopathy in acute variceal bleed: A randomized controlled trial of lactulose versus no lactulose. J. Gastroenterol. Hepatol. 2011, 26, 996–1003. [Google Scholar] [CrossRef] [PubMed]
- Wen, J.; Liu, Q.; Song, J.; Tong, M.; Peng, L.; Liang, H. Lactulose is highly potential in prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: Results of a controlled randomized trial. Digestion 2013, 87, 132–138. [Google Scholar] [CrossRef]
- Rattanasupar, A.; Chang, A.; Akarapatima, K.; Chaojin, T.; Piratvisuth, T. Role of lactulose for prophylaxis against hepatic encephalopathy in cirrhotic patients with upper gastrointestinal bleeding: A randomized trial. Indian J. Gastroenterol. 2021, 40, 621–629. [Google Scholar] [CrossRef]
- Schepis, F.; Vizzutti, F.; Garcia-Tsao, G.; Marzocchi, G.; Rega, L.; De Maria, N.; Di Maira, T.; Gitto, S.; Caporali, C.; Colopi, S.; et al. Under-dilated TIPS associate with efficacy and reduced encephalopathy in a prospective, non-randomized study of patients with cirrhosis. Clin. Gastroenterol. Hepatol. 2018, 16, 1153–1162.e7. [Google Scholar] [CrossRef] [Green Version]
- Riggio, O.; Ridola, L.; Angeloni, S.; Cerini, F.; Pasquale, C.; Attili, A.F.; Fanelli, F.; Salvatori, F.M. Clinical efficacy of transjugular, intrahepatic portosystemic shunt created with covered stents with different diameters: Results of a randomized controlled trial. J. Hepatol. 2010, 53, 267–272. [Google Scholar] [CrossRef]
- Riggio, O.; Masini, A.; Efrati, C.; Nicolao, F.; Angeloni, S.; Salvatori, F.M.; Bezzi, M.; Attili, A.F.; Merli, M. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: A randomized controlled study. J. Hepatol. 2005, 42, 674–679. [Google Scholar] [CrossRef]
- Bureau, C.; Thabut, D.; Jezequel, C.; Archambeaud, I.; D’Alteroche, L.; Dharancy, S.; Borentain, P.; Oberti, F.; Plessier, A.; De Ledinghen, V.; et al. The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt: A Randomized Controlled Trial. Ann. Intern. Med. 2021, 174, 633–640. [Google Scholar] [CrossRef] [PubMed]
- Copelan, A.; Kapoor, B.; Sands, M. Transjugular intrahepatic portosystemic shunt: Indications, contraindications, and patient work-up. Semin. Intervent. Radiol. 2014, 31, 235–242. [Google Scholar] [PubMed] [Green Version]
- Lv, Y.; Chen, H.; Luo, B.; Bai, W.; Li, K.; Wang, Z.; Xia, D.; Guo, W.; Wang, Q.; Li, X.; et al. Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial. Hepatology 2022, 76, 676–688. [Google Scholar] [CrossRef] [PubMed]
- Hartmann, I.J.; Groeneweg, M.; Quero, J.C.; Beijeman, S.J.; de Man, R.A.; Hop, W.C.; Schalm, S.W. The prognostic significance of subclinical hepatic encephalopathy. Am. J. Gastroenterol. 2000, 95, 2029–2034. [Google Scholar] [CrossRef] [PubMed]
- Nardelli, S.; Gioia, S.; Pasquale, C.; Pentassuglio, I.; Farcomeni, A.; Merli, M.; Salvatori, F.M.; Nikolli, L.; Torrisi, S.; Greco, F.; et al. Cognitive impairment predicts the occurrence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Am. J. Gastroenterol. 2016, 111, 523–528. [Google Scholar] [CrossRef] [Green Version]
- Watanabe, A.; Sakai, T.; Sato, S.; Imai, F.; Ohto, M.; Arakawa, Y.; Toda, G.; Kobayashi, K.; Muto, Y.; Tsujii, T.; et al. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997, 26, 1410–1414. [Google Scholar] [CrossRef]
- Román, E.; Nieto, J.C.; Gely, C.; Vidal, S.; Pozuelo, M.; Poca, M.; Juárez, C.; Guarner, C.; Manichanh, C.; Soriano, G. Effect of a multistrain probiotic on cognitive function and risk of falls in patients with cirrhosis: A randomized trial. Hepatol. Commun. 2019, 3, 632–645. [Google Scholar] [CrossRef] [Green Version]
- Bajaj, J.S.; Hafeezullah, M.; Hoffmann, R.G.; Saeian, K. Minimal hepatic encephalopathy: A vehicle for accidents and traffic violations. Am. J. Gastroenterol. 2007, 102, 1903–1909. [Google Scholar] [CrossRef]
- De Rui, M.; Schiff, S.; Aprile, D.; Angeli, P.; Bombonato, G.; Bolognesi, M.; Sacerdoti, D.; Gatta, A.; Merkel, C.; Amodio, P.; et al. Excessive daytime sleepiness and hepatic encephalopathy: It is worth asking. Metab. Brain Dis. 2013, 28, 245–248. [Google Scholar] [CrossRef]
- Hassouneh, R.; Bajaj, J.S. Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment. J. Clin. Med. 2021, 10, 330. [Google Scholar] [CrossRef]
- Bajaj, J.S.; Saeian, K.; Christensen, K.M.; Hafeezullah, M.; Varma, R.R.; Franco, J.; Pleuss, J.A.; Krakower, G.; Hoffmann, R.G.; Binion, D.G. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am. J. Gastroenterol. 2008, 103, 1707–1715. [Google Scholar] [CrossRef] [PubMed]
- Park, J.H.; Kang, M.; Jun, D.W.; Kim, M.; Kwak, J.H.; Kang, B.K. Determining Whether Low Protein Intake (<1.0 g/kg) Is a Risk Factor for Malnutrition in Patients with Cirrhosis. J. Clin. Med. 2021, 10, 2164. [Google Scholar] [PubMed]
- Bhanji, R.A.; Moctezuma-Velazquez, C.; Duarte-Rojo, A.; Ebadi, M.; Ghosh, S.; Rose, C.; Montano-Loza, A.J. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis. Hepatol. Int. 2018, 12, 377–386. [Google Scholar] [CrossRef] [PubMed]
- Gioia, S.; Merli, M.; Nardelli, S.; Lattanzi, B.; Pitocchi, F.; Ridola, L.; Riggio, O. The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS. Liver Int. 2019, 39, 871–877. [Google Scholar] [CrossRef]
- Gioia, S.; Ridola, L.; Cristofaro, L.; Merli, M.; Faccioli, J.; Riggio, O.; Nardelli, S. The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Liver Int. 2021, 41, 2965–2973. [Google Scholar] [CrossRef]
- Maharshi, S.; Sharma, B.C.; Sachdeva, S.; Srivastava, S.; Sharma, P. Efficacy of Nutritional Therapy for Patients with Cirrhosis and Minimal Hepatic Encephalopathy in a Randomized Trial. Clin. Gastroenterol. Hepatol. 2016, 14, 454–460.e3. [Google Scholar] [CrossRef] [Green Version]
- Roman, E.; Garcia-Galceran, C.; Torrades, T.; Herrera, S.; Marin, A.; Donate, M.; Alvarado-Tapias, E.; Malouf, J.; Nácher, L.; Serra-Grima, R.; et al. Effects of an exercise programme on functional capacity, body composition and risk of falls in patients with cirrhosis: A randomized clinical trial. PLoS ONE 2016, 11, e0151652. [Google Scholar] [CrossRef]
- Hiraoka, A.; Michitaka, K.; Kiguchi, D.; Izumoto, H.; Ueki, H.; Kaneto, M.; Kitahata, S.; Aibiki, T.; Okudaira, T.; Tomida, H.; et al. Efficacy of branched-chain amino acid supplementation and walking exercise for preventing sarcopenia in patients with liver cirrhosis. Eur. J. Gastroenterol. Hepatol. 2017, 29, 1416–1423. [Google Scholar] [CrossRef]
- Caraceni, P.; Riggio, O.; Angeli, P.; Alessandria, C.; Neri, S.; Foschi, F.G.; Levantesi, F.; Airoldi, A.; Boccia, S.; Svegliati-Baroni, G.; et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): An open-label randomised trial. Lancet 2018, 391, 2417–2429. [Google Scholar] [CrossRef]
- Ventura-Cots, M.; Simón-Talero, M.; Poca, M.; Ariza, X.; Masnou, H.; Sanchez, J.; Llop, E.; Cañete, N.; Martín-Llahí, M.; Amador, A.; et al. Effects of Albumin on Survival after a Hepatic Encephalopathy Episode: Randomized Double-Blind Trial and Meta-Analysis. J. Clin. Med. 2021, 10, 4885. [Google Scholar] [CrossRef]
- Nardelli, S.; Gioia, S.; Faccioli, J.; Riggio, O.; Ridola, L. Albumin for cognitive impairment after TIPS: A road to be explored. J. Hepatol. 2023, 78, e96–e97. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Faccioli, J.; Nardelli, S.; Gioia, S.; Riggio, O.; Ridola, L. Primary Prophylaxis of Overt Hepatic Encephalopathy: Is It Time to Consider It? J. Clin. Med. 2023, 12, 3903. https://doi.org/10.3390/jcm12123903
Faccioli J, Nardelli S, Gioia S, Riggio O, Ridola L. Primary Prophylaxis of Overt Hepatic Encephalopathy: Is It Time to Consider It? Journal of Clinical Medicine. 2023; 12(12):3903. https://doi.org/10.3390/jcm12123903
Chicago/Turabian StyleFaccioli, Jessica, Silvia Nardelli, Stefania Gioia, Oliviero Riggio, and Lorenzo Ridola. 2023. "Primary Prophylaxis of Overt Hepatic Encephalopathy: Is It Time to Consider It?" Journal of Clinical Medicine 12, no. 12: 3903. https://doi.org/10.3390/jcm12123903